Skip to main content

Table 1 Clinical characteristics of reported MS patients (with or without HIV infection) treated with antiretroviral medication

From: Human immunodeficiency virus and multiple sclerosis: a review of the literature

  Sex Age at MS diagnosis Age at HIV diagnosis MS type HIV treatment Disease-modifying MS therapy MS course Follow-up (years)
(Chalkley & Berger, 2014) [7] M 32 32 RRMS tenofovir, emtricitabine, nelfinavir none NEDA 8
(Maruszak et al., 2011) [31] M 26 Months before MS diagnosis RRMS combined treatment including nevirapine, stavudine, didanosine, lamivudine none Improvement of MS symptoms, no clinical relapses 2
(Maulucci et al., 2015) [32] F 19 22 RRMS tenofovir, emtricitabine, etravirine Low-dose IFN beta-1a NEDA-3 4
(Skarlis et al., 2017) [44] M 24 36 RRMS tenofovir-disorpoxil fumarate, emtricitabine, efavirenz none Annualized relapse rate of 0.28, EDSS progression 0.14 3
(Duran et al., 2004) [14] M 32 32 RRMS efavirenz, zidovudine, lamivudine none NEDA 1.5
(Drosu et al., 2018) [13] F 25 No HIV RRMS zidovudine, lamivudine none NEDA-3 3
  1. Abbreviations: MS Multiple sclerosis, HIV Human immunodeficiency virus, M Male, F Female, RRMS Relapsing-remitting MS, INF Interferon, NEDA No evidence of disease activity [18], EDSS Expanded disability status scale